Women diagnosed with metastatic breast cancer often contend with multiple chronic conditions, with high blood pressure among the most prevalent. A recent study revealed that nearly half of these women had hypertension at diagnosis, with rates even higher among Black and Hispanic patients. Researchers aimed to determine whether better management of hypertension could improve survival outcomes in this vulnerable population.
The study found that polytherapy—treatment with multiple classes of antihypertensive medications—was linked to significantly improved survival. Compared with monotherapy, polytherapy reduced the risk of all-cause mortality by 38%.
The benefits were even more pronounced among patients who consistently adhered to their medication regimens. Women who regularly filled their prescriptions experienced a 58% reduction in the risk of death. Polytherapy also proved more effective in controlling blood pressure, with over 75% of patients achieving systolic readings below 140 mmHg during follow-up.
“Patients with metastatic breast cancer face a heavy burden of chronic conditions, yet these are often overlooked in the urgency to treat cancer itself,” said Dr. Reina Haque, lead researcher at Kaiser Permanente Southern California’s Department of Research & Evaluation. “Our findings highlight a simple but powerful message: paying close attention to comorbidities can help extend life, particularly for women of color who have historically experienced disparities in cancer outcomes.”
The research emphasizes the importance of coordinated care across oncology, cardiology, and primary care. With polytherapy linked to lower mortality, clinicians may consider prioritizing hypertension control as a critical component of survivorship care alongside cancer treatment. Future studies will focus on identifying optimal antihypertensive regimens and integrated care models to further reduce disparities and improve patient outcomes.
